Home
Forums
New Posts
Illini Basketball
Illini Football
Sports Talk
Log in
Register
What's new
Menu
Log in
Register
Install the app
Install
Forums
General
Chat
Trading Stock/Investing
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="DaytonIllini" data-source="post: 1041496"><p>The stock is up from 91.50 on August 1 to 109 in premarket trading today. Big news was that Merck's competing regimen failed. Sovaldi which is Gilead's drug is already being replaced by Harvoni which is a cocktail that contains Sovaldi. There is still at least 1 more competing regimen undergoing trials right now. I believe that is the J&J product. If that fails this stock could easily see 120-125. Of course if it is successful you'd probably want out of this stock. A lot of its profits stem from anti-HIV drugs whose patents are creeping towards expiration.</p></blockquote><p></p>
[QUOTE="DaytonIllini, post: 1041496"] The stock is up from 91.50 on August 1 to 109 in premarket trading today. Big news was that Merck's competing regimen failed. Sovaldi which is Gilead's drug is already being replaced by Harvoni which is a cocktail that contains Sovaldi. There is still at least 1 more competing regimen undergoing trials right now. I believe that is the J&J product. If that fails this stock could easily see 120-125. Of course if it is successful you'd probably want out of this stock. A lot of its profits stem from anti-HIV drugs whose patents are creeping towards expiration. [/QUOTE]
Verification
Post reply
Forums
General
Chat
Trading Stock/Investing
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…